{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:29:24Z","timestamp":1773952164510,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1097\/rlu.0000000000001673","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T18:07:54Z","timestamp":1494094074000},"page":"e345-e346","source":"Crossref","is-referenced-by-count":23,"title":["Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET\/CT in a Patient With Malignant Melanoma"],"prefix":"10.1097","volume":"42","author":[{"given":"Roy A.","family":"Raad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajni","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Madden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-34-20210204","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2214\/ajr.180.5.1801251","article-title":"Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications","volume":"180","author":"Kim","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"R2-34-20210204","doi-asserted-by":"crossref","first-page":"W80","DOI":"10.1097\/RTI.0b013e318224cfbc","article-title":"\u201cReversed halo sign\u201d","volume":"26","author":"Walker","year":"2011","journal-title":"J Thorac Imaging"},{"key":"R3-34-20210204","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-34-20210204","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-34-20210204","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-34-20210204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti\u2013CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"R7-34-20210204","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R8-34-20210204","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-34-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"Radiographics"},{"key":"R10-34-20210204","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"R11-34-20210204","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"R12-34-20210204","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RLU.0000000000000606","article-title":"Ipilimumab-induced hepatitis on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"40","author":"Raad","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R13-34-20210204","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"key":"R14-34-20210204","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1179\/2295333715Y.0000000047","article-title":"Unusual pulmonary toxicity of ipilimumab treated by macrolides","volume":"70","author":"Mailleux","year":"2015","journal-title":"Acta Clin Belg"},{"key":"R15-34-20210204","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1183\/09031936.06.00013505","article-title":"Cryptogenic organising pneumonia","volume":"28","author":"Cordier","year":"2006","journal-title":"Eur Respir J"},{"key":"R16-34-20210204","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1136\/thx.2008.101691","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000001673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:18:54Z","timestamp":1620973134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201707000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001673","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}